A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study Evaluating LY3848575 in Chronic Neuropathic Pain Associated With Distal Sensory Polyneuropathy
Latest Information Update: 28 May 2025
At a glance
- Drugs LY 3848575 (Primary)
- Indications Neuropathic pain; Polyneuropathy
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
Most Recent Events
- 22 Oct 2024 Status changed from not yet recruiting to recruiting.
- 26 Aug 2024 New trial record